Pharmacopius Drugs Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.48 M
- Company Age 19 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 8.18%
- Profit Growth 15.11%
- Ebitda -11.46%
- Net Worth 7.28%
- Total Assets 0.61%
About Pharmacopius Drugs
Pharmacopius Drugs Private Limited (PDPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 13 July 2005 and has a history of 19 years and six months. Its registered office is in Kottayam, Kerala, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.48 M, as per Ministry of Corporate Affairs (MCA) records.
Thekkemadathil Manikandan and Aju Varghese serve as directors at the Company.
Company Details
-
Location
Kottayam, Kerala, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232KL2005PTC018418
-
Company No.
018418
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
13 Jul 2005
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Pharmacopius Drugs?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Thekkemadathil Manikandan
|
Managing Director | 13-Jul-2005 | Current |
|
Aju Varghese
|
Managing Director | 13-Jul-2005 | Current |
Board Members
No Directors or KMP associated with company. Upon reviewing the records, we can confirm that there are no Directors or Key Management Personnel (KMP) associated with this company at present.
Financial Performance of Pharmacopius Drugs.
Pharmacopius Drugs Private Limited, for the financial year ended 2024, experienced modest growth in revenue, with a 8.18% increase. The company also saw a substantial improvement in profitability, with a 15.11% increase in profit. The company's net worth moved up by a moderate rise of 7.28%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pharmacopius Drugs?
Unlock access to Pharmacopius Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Pharmacopius Drugs?
Pharmacopius Drugs has a workforce of 33 employees as of Nov 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pharmacopius Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pharmacopius Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
